Abstract:Aims: Iron metabolism is involved in many biological processes in the brain. Alterations in iron homeostasis have been associated with several neurodegenerative disorders. Instead of stroke and ischemic heart disease, dementia has become the second leading cause of mortality among the type 2 diabetes mellitus (T2DM) population. Therefore, we attempted to investigate the role of ferroptosis in the diabetes-associated cognitive dysfunction (DACD). Results: We evaluated ferroptosis hallmarks in the hippocampus of T2DM mice, primary hippocampal neurons and blood of patients. The results of Gene Set Enrichment Analysis showed significantly different genes related to ferroptosis-related pathways between db/m and db/db mice. Here, ferroptosis, mitochondrial dysfunction and cognitive impairment were found and caveolin-1 (cav-1) was significantly downregulated in the hippocampus of T2DM mice. Whereas both of ferrostatin-1 and cav-1 restoration neutralized ferroptosis-related symbolic changes, mitochondrial dysfunction and improved cognitive dysfunction. Notably, the plasma levels of iron and 4-HNE in T2DM patients were much higher compared to those in non-diabetic subjects, and Fe2+ level negatively correlated with the cognitive ability in T2DM subjects. Innovation: This study for the first time suggests that ferroptosis promotes the progression of DACD induced by T2DM in vivo and in vitro, and supports the clinical evidence for the correlation between ferroptosis and T2DM-related DACD, which provides new insights into the potential antioxidant effects of ferroptosis inhibitors and cav-1 on DACD. Conclusions: The overexpression of cav-1 may attenuate DACD by modulating neuronal ferroptosis-mediated mitochondrial homeostasis. We put cav-1 on the spotlight as a promising candidate to prevent DACD.

Caveolin-1 alleviates diabetes-associated cognitive dysfunction through modulating neuronal ferroptosis-mediated mitochondrial homeostasis